Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Lu, Hao K ^a,b   Gray, Lachlan R ^a,b   Wightman, Fiona ^a,b   Ellenberg, Paula ^a,b   Khoury, Gabriela ^a,b   Cheng, Wan Jung ^b   Mota, Talia M ^a,b,c   Wesselingh, Steve ^b,d   Gorry, Paul R ^a,b,c   Cameron, Paul U ^a,b,e   Churchill, Melissa J ^a,b   Lewin, Sharon R ^a,b,c,e  

^a MONASH UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^e ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; TRANSACTIVATOR PROTEIN; TRICHOSTATIN A; VORINOSTAT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZAMIDE DERIVATIVE; HYDROXAMIC ACID; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; ASTROCYTE; CASE REPORT; CD4+ T LYMPHOCYTE; CELL TYPE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESPONSE; EPISOME; EPITHELIUM CELL; EX VIVO STUDY; GENE AMPLIFICATION; GENE VECTOR; HELA CELL LINE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LONG TERMINAL REPEAT; MEMORY T LYMPHOCYTE; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; VIRUS ISOLATION; VIRUS STRAIN; VIRUS TRANSCRIPTION; BLOOD; CELL LINE; DRUG EFFECTS; HIV INFECTIONS; OBSERVATIONAL STUDY; PHYLOGENY; T LYMPHOCYTE; VIROLOGY;

ADULT; AGED; ANTI-HIV AGENTS; BENZAMIDES; CELL LINE; HELA CELLS; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HUMANS; HYDROXAMIC ACIDS; INDOLES; OBSERVATIONAL STUDY AS TOPIC; PHYLOGENY; PYRIDINES; T-LYMPHOCYTES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84911899230     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113341     Document Type: Article

References (48)

1. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature medicine 9: 727-728.
2. Wightman F, Solomon A, Khoury G, Green JA, Gray L, et al. (2010) Both CD31(+) and CD31(-) naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy. The Journal of infectious diseases 202: 1738-1748.
3. Wightman F, Ellenberg P, Churchill M, Lewin SR (2012) HDAC inhibitors in HIV. Immunology and cell biology 90: 47-54.
4. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM (2004) Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18: 1101-1108.
5. Shehu-Xhilaga M, Rhodes D, Wightman F, Liu HB, Solomon A, et al. (2009) The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. AIDS 23: 2047-2050.
6. Savarino A, Mai A, Norelli S, El Daker S, Valente S, et al. (2009) "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 6: 52.
7. Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, et al. (2009) A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. Journal of virology 83: 4749-4756.
8. Archin NM, Keedy KS, Espeseth A, Dang H, Hazuda DJ, et al. (2009) Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 23: 1799-1806.
9. Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M Jr, et al. (2014) Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America.
10. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, et al. (2013) An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS pathogens 9: e1003834.
11. Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, et al. (2012) Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients. AIDS 26: 1473-1482.
12. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487: 482-485.
13. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF (2014) New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nature medicine 20: 425-429.
14. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, el al. (2014) Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet 1: e13-e21.
15. Elliott JH, Wightman F, Solomon AE, Ghneim K, Ahlers J, et al. (2014) Activation of HIV Transcription with Short-course Vorinostat in HIV-infected Patients on Suppressive Antiretroviral Therapy. PLoS pathogens. In Press
16. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, et al. (2008) Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. Journal of virology 82: 3952-3970.
17. Clouse KA, Powell D, Washington I, Poli G, Strebel K, et al. (1989) Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. Journal of immunology 142: 431-438.
18. Major EO, Miller AE, Mourrain P, Traub RG, de Widt E, et al. (1985) Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proceedings of the National Academy of Sciences of the United States of America 82: 1257-1261.
19. Zeichner SL, Kim JY, Alwine JC (1991) Linker-scanning mutational analysis of the transcriptional activity of the human immunodeficiency virus type 1 long terminal repeat. Journal of virology 65: 2436-2444.
20. Gray LR, Cowley D, Crespan E, Welsh C, Mackenzie C, et al. (2013) Reduced basal transcriptional activity of central nervous system-derived HIV type 1 long terminal repeats. AIDS Res Hum Retroviruses 29: 365-370.
21. Einav Y, Shistik E, Shenfeld M, Simons AH, Melton DW, et al. (2003) Replication and episomal maintenance of Epstein-Barr virus-based vectors in mouse embryonal fibroblasts enable synthetic lethality screens. Mol Cancer Ther 2: 1121-1128.
22. Zhu H, Geiman TM, Xi S, Jiang Q, Schmidtmann A, et al. (2006) Lsh is involved in de novo methylation of DNA. The EMBO journal 25: 335-345.
23. Hodin TL, Najrana T, Yates JL (2013) Efficient Replication of Epstein-Barr Virus-Derived Plasmids Requires Tethering by EBNA1 to Host Chromosomes. Journal of virology 87: 13020-13028.
24. Berkhout B, Jeang KT (1992) Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat. Journal of virology 66: 139-149.
25. Kamine J, Subramanian T, Chinnadurai G (1993) Activation of a heterologous promoter by human immunodeficiency virus type 1 Tat requires Sp1 and is distinct from the mode of activation by acidic transcriptional activators. Journal of virology 67: 6828-6834.
26. Kumar S, Maiti S (2013) The Effect of N-acetylation and N-methylation of Lysine Residue of Tat Peptide on its Interaction with HIV-1 TAR RNA. PloS one 8: e77595.
27. He M, Zhang L, Wang X, Huo L, Sun L, et al. (2013) Systematic Analysis of the Functions of Lysine Acetylation in the Regulation of Tat Activity. PloS one 8: e67186.
28. Sakane N, Kwon HS, Pagans S, Kaehlcke K, Mizusawa Y, et al. (2011) Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). PLoS pathogens 7: e1002184.
29. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, et al. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11: 435-442.
30. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, et al. (2013) Replicationcompetent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure. Cell 155: 540-551.
31. Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM (2013) Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. The Journal of biological chemistry 288: 14400-14407.
32. Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, et al. (2010) Combinatorial latency reactivation for HIV-1 subtypes and variants. Journal of virology 84: 5958-5974.
33. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nature reviews Drug discovery 5: 769-784.
34. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, et al. (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193.
35. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, et al. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. The Biochemical journal 409: 581-589.
36. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, et al. (2014) Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing. PLoS pathogens 10: e1004071.
37. Shan L, Xing S, Yang HC, Zhang H, Margolick JB, et al. (2014) Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells. J Antimicrob Chemother 69: 28-33.
38. Rasmussen TA, Schmeltz Sogaard O, Brinkmann C, Wightman F, Lewin SR, et al. (2013) Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 9: 993-1001.
39. Wightman F, Lu HK, Solomon AE, Saleh S, Harman AN, et al. (2013) Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS 27: 2853-2862.
40. Kato TA, Tsuda A, Uesaka M, Fujimori A, Kamada T, et al. (2011) In vitro characterization of cells derived from chordoma cell line U-CH1 following treatment with X-rays, heavy ions and chemotherapeutic drugs. Radiat Oncol 6: 116.
41. Marelli-Berg FM, Fu H, Mauro C (2012) Molecular mechanisms of metabolic reprogramming in proliferating cells: implications for T-cell-mediated immunity. Immunology 136: 363-369.
42. Barboric M, Yik JH, Czudnochowski N, Yang Z, Chen R, et al. (2007) Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription. Nucleic Acids Res 35: 2003-2012.
43. Barboric M, Lenasi T (2010) Kick-sTARting HIV-1 transcription elongation by 7SK snRNP deporTATion. Nat Struct Mol Biol 17: 928-930.
44. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, et al. (2009) Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. The Journal of biological chemistry 284: 6782-6789.
45. Ramakrishnan R, Liu H, Rice AP (2014) SAHA (Vorinostat) Induces CDK9 Thr-186 (T-Loop) Phosphorylation in Resting CD4 T Cells: Implications for Reactivation of Latent HIV. AIDS Res Hum Retroviruses.
46. Kiernan RE, Vanhulle C, Schiltz L, Adam E, Xiao H, et al. (1999) HIV-1 tat transcriptional activity is regulated by acetylation. The EMBO journal 18: 6106-6118.
47. Van Lint C, Emiliani S, Ott M, Verdin E (1996) Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. The EMBO journal 15: 1112-1120.
48. Verdin E, Paras P Jr, Van Lint C (1993) Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. The EMBO journal 12: 3249-3259.